Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Total Liabilities (2009 - 2025)

Grifols' (GIFLF) quarterly Total Liabilities came in at $14.1 billion in Q4 2025, up 3.06% on a YoY basis from $13.7 billion in Q4 2024, and up 3.06% quarter-over-quarter from $13.7 billion in Q4 2024.

Analysis

Grifols (GIFLF) Total Liabilities (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Total Liabilities for 17 consecutive years, with $14.1 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 3.06% year-over-year to $14.1 billion; the trailing twelve-month figure through Dec 2025 stood at $14.1 billion (up 3.06% YoY), and the FY2025 full-year result was $13.7 billion, up 13182.41% from the prior year.
  • Total Liabilities advanced to $14.1 billion in Q4 2025 per GIFLF's latest filing, from $13.7 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $14.5 billion in Q4 2023 and bottomed at $13.5 billion in Q4 2022.
  • Historically, Total Liabilities has averaged $13.9 billion across 5 years, with a median of $13.7 billion in 2024.
  • The sharpest annual moves came in 2021 and 2024: Total Liabilities jumped 33.65% in 2021, then decreased 5.69% in 2024.
  • Over 5 years, Total Liabilities stood at $13.6 billion in 2021, then dropped by 0.81% to $13.5 billion in 2022, then climbed by 7.25% to $14.5 billion in 2023, then retreated by 5.69% to $13.7 billion in 2024, then advanced by 3.06% to $14.1 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods registered $14.1 billion, $13.7 billion, and $14.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 83.95 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 37.53 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 7.18 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 10.02 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 1.62 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 4.20 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 4.20 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 13.24 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 384.62 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 14.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 14.10 Bn
Dec 31, 2024 13.68 Bn
Dec 31, 2023 14.50 Bn
Dec 31, 2022 13.52 Bn
Dec 31, 2021 13.63 Bn
Dec 31, 2020 10.20 Bn
Sep 30, 2020 9.97 Bn
Mar 31, 2020 9.59 Bn
Dec 31, 2019 9.63 Bn
Sep 30, 2019 9.73 Bn
Dec 31, 2018 8.88 Bn
Sep 30, 2018 8.88 Bn
Jun 30, 2018 8.91 Bn
Mar 31, 2018 10.45 Bn
Dec 31, 2017 8.58 Bn
Jun 30, 2017 8.28 Bn
Dec 31, 2016 6.91 Bn
Sep 30, 2016 6.74 Bn
Jun 30, 2016 6.92 Bn
Mar 31, 2016 100.59 Mn